News

Qiagen N.V. (QGEN) Expands MRD Testing with Tracer and Foresight Partnerships
Qiagen N.V. (NYSE: QGEN) has announced two strategic partnerships designed to revolutionize minimal residual disease (MRD) ...
QIAGEN expands portfolio for MRD testing in oncology with two partnerships
QIAGEN expands its oncology diagnostics with partnerships advancing minimal residual disease testing for solid tumors & blood ...
360Dx3d
Qiagen Inks MRD Test Development Pacts with Foresight Diagnostics, Tracer Biotechnologies
The deals cover development and commercialization of next-generation sequencing and digital PCR assays for minimal residual disease detection.
DutchNews.nl3d
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of ...
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: ...
C&EN5d
High-Speed Atomic Force Microscopy Revealing Contamination in DNA Purification Systems
Eluates from the Zymo kits also tested positive for DNA in fluorescent intercalator dye and whole genome amplification (WGA) assays. Qiagen kits tested positive in the fluorescence assay but negative ...